Indumati Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -38.32%
- Profit Growth 123.71%
- Ebitda 55.98%
- Net Worth 4.73%
- Total Assets -3.71%
About Indumati Pharma
Indumati Pharma Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 April 2013 and has a history of 11 years and nine months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Musical Instruments Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ramadas Kute and Indumati Kute serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24240PN2013PTC146971
-
Company No.
146971
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Apr 2013
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Indumati Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramadas Kute
|
Director | 17-Apr-2013 | Current |
|
Indumati Kute
|
Director | 20-Sep-2018 | Current |
Financial Performance of Indumati Pharma.
Indumati Pharma Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 38.32% decrease. The company also saw a substantial improvement in profitability, with a 123.71% increase in profit. The company's net worth moved up by a moderate rise of 4.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indumati Pharma?
In 2017, Indumati Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Inducare Pharmaceuticals And Research FoundationRamadas Kute is a mutual person
-
Inducare Pharma Private LimitedRamadas Kute is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Indumati Pharma?
Unlock and access historical data on people associated with Indumati Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indumati Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indumati Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
